Grifols SA (GRF):企業の財務・戦略的SWOT分析

◆英語タイトル:Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1678
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Grifols SA (GRF) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) focuses on improving the health and well-being of people around the world. It conducts research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. The company has plasma donation centers across the US. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

Mar 27,2020 Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26,2020 Grifols teams up with US to test plasma therapy for Covid-19
Mar 25,2020 Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27,2020 Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Grifols SA – Key Facts
Grifols SA – Key Employees
Grifols SA – Key Employee Biographies
Grifols SA – Major Products and Services
Grifols SA – History
Grifols SA – Company Statement
Grifols SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grifols SA – Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Bioscience
Overview
Performance
Key Stats
Business Segment: Diagnostic
Overview
Performance
Key Stats
Business Segment: Hospital
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: European Union
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA – SWOT Analysis
SWOT Analysis – Overview
Grifols SA – Strengths
Grifols SA – Weaknesses
Grifols SA – Opportunities
Grifols SA – Threats
Grifols SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 27, 2020: Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26, 2020: Grifols teams up with US to test plasma therapy for Covid-19
Mar 25, 2020: Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27, 2020: Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
Feb 13, 2020: Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership
Dec 05, 2019: Grifols streamlines Hospital Pharmacy operations with new KIRO Fill technology and PharmacyKeeper enhancements
Jul 31, 2019: Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan
Jul 03, 2019: Grifols selected to build its first intravenous solutions manufacturing line in Africa
May 24, 2019: Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022
May 08, 2019: Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont...1)
Grifols SA, Annual Ratios (Cont...2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Grifols SA, Performance Chart (2015 - 2019)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Grifols SA (GRF):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LifePoint Health Inc (LPNT):製薬・医療:M&Aディール及び事業提携情報
    Summary LifePoint Health Inc (LifePoint) is a healthcare service provider which operates community hospitals, physician practices, outpatient centers, post-acute facilities and regional health systems. The company along with its subsidiaries delivers a range of medical and surgical services to non-u …
  • Bunge North America, Inc.:戦略・SWOT・企業財務分析
    Bunge North America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bunge North America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Madrigal Pharmaceuticals Inc (MDGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-319 …
  • Gibson Energy Inc (GEI):企業の財務・戦略的SWOT分析
    Gibson Energy Inc (GEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Syngen Biotech Co Ltd (8279):製薬・医療:M&Aディール及び事業提携情報
    Summary Syngen Biotech Co Ltd (Syngen) is a biotechnology company. The company manufactures and supplies active pharmaceutical ingredients (APIs), biology fermentation products, nutritional ingredients, nutraceutical ingredients, biology agriculture and aquaculture products, and functional food prod …
  • Berger Paints India Ltd (BERGEPAINT):企業の財務・戦略的SWOT分析
    Berger Paints India Ltd (BERGEPAINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Daya Materials Bhd (DAYA):企業の財務・戦略的SWOT分析
    Summary Daya Materials Bhd (DMB) is a chemical company that offers polymer compound solutions. The company provides bulk chemicals, catalysts, additives, inert support materials and deodorizing agents. Its polymer compound products include semi conductive compounds, medium-voltage XLPE compounds, lo …
  • Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular syst …
  • Viking Line ABP:企業の戦略・SWOT・財務情報
    Viking Line ABP - Strategy, SWOT and Corporate Finance Report Summary Viking Line ABP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Mauna Kea Technologies SAS (MKEA)-医療機器分野:企業M&A・提携分析
    Summary Mauna Kea Technologies SAS (MKT) is a medical device company that develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. The company’s product includes cellvizio. Its cellvizio is an endomicroscopy platform that provides micr …
  • FLIR Systems Inc:企業のM&A・事業提携・投資動向
    FLIR Systems Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's FLIR Systems Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Nexstim Plc (NXTMH)-医療機器分野:企業M&A・提携分析
    Summary Nexstim Plc (Nexstim) is a medical technology company, which focuses on navigated brain stimulation (NBS) to improve rehabilitation in stroke patients non-invasively . Its NBS system, which is FDA cleared and CE-marked, applies navigated transcranial magnetic stimulation (nTMS) device for pr …
  • LHC Group Inc (LHCG):企業の財務・戦略的SWOT分析
    Summary LHC Group Inc (LHC Group) is an in-home healthcare service provider. The center offers home health, hospice, personal care services and facility-based services. It covers a range of healthcare needs for patients and families dealing with injury, illness, and chronic conditions. LHC Group pro …
  • Follett Corporation:企業の戦略・SWOT・財務情報
    Follett Corporation - Strategy, SWOT and Corporate Finance Report Summary Follett Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Greggs Plc:企業の戦略・SWOT・財務情報
    Greggs Plc - Strategy, SWOT and Corporate Finance Report Summary Greggs Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Pulmagen Therapeutics LLP:製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmagen Therapeutics LLP (Pulmagen) formerly Argenta Discovery Ltd, is a development stage pharmaceutical company, which develops oral and inhaled medicines for chronic respiratory diseases. The company’s product pipeline includes oral CRTh2 antagonists, inhaled bronchodilators, inhaled per …
  • Glaukos Corp (GKOS):企業の財務・戦略的SWOT分析
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • Paymark:企業の戦略的SWOT分析
    Paymark - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Biglari Holdings Inc.:戦略・SWOT・企業財務分析
    Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Abzena Plc (ABZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆